Skip to main content
Top
Published in: Annals of Hematology 5/2024

Open Access 23-03-2024 | Thalassemia | Original Article

Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with β-thalassemia

Authors: Eduardo J. Bardón-Cancho, José Manuel Marco-Sánchez, David Benéitez-Pastor, Salvador Payán-Pernía, Anna Ruiz Llobet, Rubén Berrueco, Marina García-Morin, Cristina Beléndez, Leonor Senent, María José Ortega Acosta, Irene Peláez Pleguezuelos, Pablo Velasco, Anna Collado, Marta Moreno-Servet, Bienvenida Argilés, Inmaculada Pérez de Soto, María del Mar Bermúdez, Eduardo J. Salido Fiérrez, Adoración Blanco-Álvarez, Pablo González Navarro, Elena Cela

Published in: Annals of Hematology | Issue 5/2024

Login to get access

Abstract

Introduction

The increase in the number of patients with hemoglobinopathies in Europe in recent decades highlights the need for more detailed epidemiological information in Spain. To fulfil this need, the Spanish Society of Pediatric Hematology and Oncology (SEHOP) sponsored the creation of a national registry of hemoglobinopathies known as REHem-AR (Spanish Registry of Hemoglobinopathies and Rare Anemias). Data from the transfusion-dependent (TDT) and non–transfusion-dependent (NTDT) β-thalassemia cohorts are described and analyzed.

Methods

We performed an observational, multicenter, and ambispective study, which included patients of any age with TDT and NTDT, registered up to December 31, 2021.

Results

Among the 1741 patients included, 168 cases of thalassemia were identified (103 TDT and 65 NTDT-patients). Survival at 18 years was 93% for TDT and 100% for NTDT. Regarding management, 80 patients with TDT (77.7%) and 23 patients with NTDT (35.4%) started chelation treatment during follow-up, with deferasirox being the most widely used. A total of 76 patients within the TDT cohort presented at least 1 complication (73.8%), the most frequent being hemosiderosis and osteopenia-osteoporosis. Comparison of both cohorts revealed significant differences in the diagnosis of hepatic hemosiderosis (p = 0.00024), although these were not observed in the case of cardiac iron overload (p = 0.27).

Discussion

Our registry enabled us to describe the management of β thalassemia in Spain and to analyze the morbidity and mortality of the cohorts of patients with TDT and NTDT. Complications related to iron overload in TDT and NTDT account for most of the morbidity and mortality of the disease, which is associated with a considerable social, psychological, and economic impact, although cardiac, osteopathy and endocrinological complications requiring more attention. The convenience and simplicity of online registries make it possible to homogenize variables and periodically update data, thus providing valuable information on these diseases.
Literature
1.
go back to reference Voskaridou E, Kattamis A, Fragodimitri C, Greek Haemoglobinopathies Study Group et al (2019) National registry of hemoglobinopathies in Greece: updated demographics, current trends in affected births, and causes of mortality. Ann Hematol 98(1):55–66CrossRefPubMed Voskaridou E, Kattamis A, Fragodimitri C, Greek Haemoglobinopathies Study Group et al (2019) National registry of hemoglobinopathies in Greece: updated demographics, current trends in affected births, and causes of mortality. Ann Hematol 98(1):55–66CrossRefPubMed
2.
go back to reference Modell B, Khan M, Darlison M et al (2001) A national register for surveillance of inherited disorders: beta thalassaemia in the United Kingdom. Bull World Health Organ 79(11):1006–1013 PMID: 11731807; PMCID: PMC2566700PubMedPubMedCentral Modell B, Khan M, Darlison M et al (2001) A national register for surveillance of inherited disorders: beta thalassaemia in the United Kingdom. Bull World Health Organ 79(11):1006–1013 PMID: 11731807; PMCID: PMC2566700PubMedPubMedCentral
7.
go back to reference Modell B, Khan M, Darlison M (2000) Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355(9220):2051–2052CrossRefPubMed Modell B, Khan M, Darlison M (2000) Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355(9220):2051–2052CrossRefPubMed
8.
go back to reference Conte R, Ruggieri L, Gambino A et al (2016) The Italian multiregional thalassemia registry: centers characteristics, services, and patients’ population. Hematology 21(7):415–424 Epub 2016 Feb 22. PMID: 26863102CrossRefPubMed Conte R, Ruggieri L, Gambino A et al (2016) The Italian multiregional thalassemia registry: centers characteristics, services, and patients’ population. Hematology 21(7):415–424 Epub 2016 Feb 22. PMID: 26863102CrossRefPubMed
11.
go back to reference Cela E, Bellón JM, de la Cruz M et al (2017) SEHOP-Hemoglobinopathies Study Group (Sociedad Española De Hematología Y Oncología Pediátricas). National registry of hemoglobinopathies in Spain (REPHem). Pediatr Blood Cancer 64(7). https://doi.org/10.1002/pbc.26322Epub 2016 Nov 2. PMID: 27804209 Cela E, Bellón JM, de la Cruz M et al (2017) SEHOP-Hemoglobinopathies Study Group (Sociedad Española De Hematología Y Oncología Pediátricas). National registry of hemoglobinopathies in Spain (REPHem). Pediatr Blood Cancer 64(7). https://​doi.​org/​10.​1002/​pbc.​26322Epub 2016 Nov 2. PMID: 27804209
12.
go back to reference Bardón Cancho EJ, García-Morín M, Beléndez C et al (2020) Update of the Spanish registry of haemoglobinopathies in children and adults. Med Clin (Barc) 155(3):95–103 English. Spanish. doi:. https://doi.org/10.1016/j.medcli.2019.10.011. en representación del grupo de trabajo de Eritropatología de la Sociedad Española de Hematología y Oncología Pediátricas (SEHOP) Bardón Cancho EJ, García-Morín M, Beléndez C et al (2020) Update of the Spanish registry of haemoglobinopathies in children and adults. Med Clin (Barc) 155(3):95–103 English. Spanish. doi:. https://​doi.​org/​10.​1016/​j.​medcli.​2019.​10.​011. en representación del grupo de trabajo de Eritropatología de la Sociedad Española de Hematología y Oncología Pediátricas (SEHOP)
21.
22.
go back to reference Baronciani D, Angelucci E, Potschger U et al (2016) Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000–2010. Bone Marrow Transplant. ;51(4):536 – 41. https://doi.org/10.1038/bmt.2015.293. PMID: 26752139 Baronciani D, Angelucci E, Potschger U et al (2016) Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000–2010. Bone Marrow Transplant. ;51(4):536 – 41. https://​doi.​org/​10.​1038/​bmt.​2015.​293. PMID: 26752139
23.
go back to reference Bonifazi F, Conte R, Baiardi P, HTA-THAL Multiregional Registry et al (2017) Pattern of complications and burden of disease in patients affected by beta thalassemia major. Curr Med Res Opin 33(8):1525–1533 Epub 2017 Jun 7. PMID: 28471307CrossRefPubMed Bonifazi F, Conte R, Baiardi P, HTA-THAL Multiregional Registry et al (2017) Pattern of complications and burden of disease in patients affected by beta thalassemia major. Curr Med Res Opin 33(8):1525–1533 Epub 2017 Jun 7. PMID: 28471307CrossRefPubMed
28.
go back to reference Izadyar S, Fazeli M, Izadyar M et al (2012) Bone mineral density in adult patients with major thalassaemia: our experience and a brief review of the literature. Endokrynol Pol 63(4):264–269 PMID: 22933161PubMed Izadyar S, Fazeli M, Izadyar M et al (2012) Bone mineral density in adult patients with major thalassaemia: our experience and a brief review of the literature. Endokrynol Pol 63(4):264–269 PMID: 22933161PubMed
32.
go back to reference De Sanctis V, Eleftheriou A, Malaventura C, Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia (2004) ;. Prevalence of endocrine complications and short stature in patients with Thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev. ;2 Suppl 2:249 – 55. PMID: 16462705. De Sanctis V, Eleftheriou A, Malaventura C, Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia (2004) ;. Prevalence of endocrine complications and short stature in patients with Thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev. ;2 Suppl 2:249 – 55. PMID: 16462705.
33.
go back to reference Regalado-Artamendi I, Pérez-Corral AM, García-Morín M et al (2021) Complete RH and Kell matching related to low alloimmunisation risk in sickle cell disease: prevalence and risk factors of alloimmunisation in a Spanish Tertiary Care National Reference Centre. Blood Transfus 19(4):292–299 Epub 2020 Oct 14. PMID: 33085598; PMCID: PMC8297678PubMedPubMedCentral Regalado-Artamendi I, Pérez-Corral AM, García-Morín M et al (2021) Complete RH and Kell matching related to low alloimmunisation risk in sickle cell disease: prevalence and risk factors of alloimmunisation in a Spanish Tertiary Care National Reference Centre. Blood Transfus 19(4):292–299 Epub 2020 Oct 14. PMID: 33085598; PMCID: PMC8297678PubMedPubMedCentral
Metadata
Title
Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with β-thalassemia
Authors
Eduardo J. Bardón-Cancho
José Manuel Marco-Sánchez
David Benéitez-Pastor
Salvador Payán-Pernía
Anna Ruiz Llobet
Rubén Berrueco
Marina García-Morin
Cristina Beléndez
Leonor Senent
María José Ortega Acosta
Irene Peláez Pleguezuelos
Pablo Velasco
Anna Collado
Marta Moreno-Servet
Bienvenida Argilés
Inmaculada Pérez de Soto
María del Mar Bermúdez
Eduardo J. Salido Fiérrez
Adoración Blanco-Álvarez
Pablo González Navarro
Elena Cela
Publication date
23-03-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 5/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-05694-z

Other articles of this Issue 5/2024

Annals of Hematology 5/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.